Company intelligence / Profile preview

Stromatis Pharma

Georgia, United States

Ownership: Private
Development stage: Other

Overview

Stromatis Pharma's lead programs are preclinical monoclonal antibodies and antibody-drug conjugates focused on dual-targeting of CEACAM5 and CEACAM6, a CAR-T platform, and a pioneering antibody antagonist of sFRP2 for cancer and fibrosis. Published results show potent anti-tumor activity in animal models for pancreatic ductal adenocarcinoma and other neoplasms, but no clinical data in humans yet

Therapeutic areas: OncologyPulmonology
Modalities: Monoclonal antibodyAntibody-drug conjugateCAR-T cell therapy
Industry: Biotech

Drug pipeline

7 assets

CT109

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Collaborates with academic medical centers (UC Davis, Johns Hopkins—via manufacturing/GMP grants referenced in parent company materials)

Beyond the preview

Go deeper on Stromatis Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stromatis Pharma.

Explore the full profile